Ewing Sarcoma Clinical Trials

37 recruiting

Ewing Sarcoma Trials at a Glance

43 actively recruiting trials for ewing sarcoma are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 1 with 23 trials, with the heaviest enrollment activity in New York, Philadelphia, and Los Angeles. Lead sponsors running ewing sarcoma studies include St. Jude Children's Research Hospital, Istituto Ortopedico Rizzoli, and Children's Hospital of Philadelphia.

Browse ewing sarcoma trials by phase

Treatments under study

About Ewing Sarcoma Clinical Trials

Looking for clinical trials for Ewing Sarcoma? There are currently 37 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Ewing Sarcoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Ewing Sarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 43 trials

Recruiting
Phase 1

A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

Prostate CancerEwing SarcomaOther Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.110 enrolled3 locationsNCT06926283
Recruiting
Not Applicable

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

Metastatic SarcomaEwing SarcomaRhabdomyosarcoma+1 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins70 enrolled2 locationsNCT06796543
Recruiting
Phase 1

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

Ewing Sarcoma
Amgen50 enrolled3 locationsNCT07297979
Recruiting
Phase 1

Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

Germ Cell TumorEwing SarcomaNeuroblastoma+3 more
New York Medical College30 enrolled1 locationNCT04308330
Recruiting
Phase 1

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Soft Tissue SarcomaMelanomaCarcinoma+13 more
St. Jude Children's Research Hospital48 enrolled1 locationNCT04897321
Recruiting
Phase 1Phase 2

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Solid Tumor+19 more
St. Jude Children's Research Hospital90 enrolled10 locationsNCT04901702
Recruiting
Phase 1Phase 2

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

OsteosarcomaEwing SarcomaNeuroblastoma+2 more
Milton S. Hershey Medical Center104 enrolled21 locationsNCT06541262
Recruiting
Phase 1Phase 2

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

OsteosarcomaEwing SarcomaNeuroblastoma+4 more
Milton S. Hershey Medical Center289 enrolled10 locationsNCT06465199
Recruiting
Phase 1Phase 2

Lurbinectedin in FET-Fused Tumors

Ewing SarcomaPediatric CancerDesmoplastic Small Round Cell Tumor+1 more
Children's Hospital of Philadelphia63 enrolled6 locationsNCT05918640
Recruiting
Phase 1

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Ewing Sarcoma
Inhibrx Biosciences, Inc321 enrolled35 locationsNCT03715933
Recruiting
Phase 1

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

Metastatic Ewing Sarcoma
H. Lee Moffitt Cancer Center and Research Institute15 enrolled17 locationsNCT07194044
Recruiting

Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone

ChondrosarcomaBone SarcomaChordoma+2 more
Mayo Clinic72 enrolled3 locationsNCT05033288
Recruiting
Phase 1Phase 2

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

OsteosarcomaEwing SarcomaNeuroblastoma+10 more
University of Florida27 enrolled1 locationNCT06625190
Recruiting
Phase 1Phase 2

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Ovarian CarcinomaColorectal CarcinomaMelanoma+19 more
Children's Oncology Group147 enrolled21 locationsNCT04851119
Recruiting
Phase 1

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Advanced Solid TumorsEwing SarcomaHepatocellular Carcinoma (HCC)+1 more
SEED Therapeutics, Inc.171 enrolled6 locationsNCT07197554
Recruiting
Not Applicable

Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

AngiosarcomaOsteosarcomaEwing Sarcoma+4 more
Centre Leon Berard168 enrolled16 locationsNCT04055220
Recruiting
Phase 1

Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas

SarcomaEwing SarcomaChildhood Soft Tissue Sarcoma+2 more
St. Jude Children's Research Hospital42 enrolled1 locationNCT07222735
Recruiting

Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salvage Surgery

OsteosarcomaEwing SarcomaChondrosarcoma+1 more
Istituto Ortopedico Rizzoli50 enrolled1 locationNCT05779670
Recruiting
Phase 1Phase 2

Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

Ewing SarcomaRefractory Ewing SarcomaRelapsed Ewing Sarcoma
Jazz Pharmaceuticals60 enrolled15 locationsNCT05734066
Recruiting
Phase 1

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

Ewing SarcomaNeuroblastomaRhabdomyosarcoma+1 more
Children's National Research Institute18 enrolled2 locationsNCT07172958